The purpose of this study is to describe the real world effectiveness of anidulafungin in
clinical practice in a large Liver Unit in the United Kingdom.
Percentage of Participants With Unfavorable OutcomePercentage of Participants Who Died Due to All Causes
Percentage of Participants With Death Attributable to Fungal Infection
Percentage of Participants With Death Unrelated to Fungal Infection
Percentage of Participants With Favorable Clinical Response
Percentage of Participants With Lack of Clinical Response
Percentage of Participants Requiring Change or Additional Antifungal Therapy
Percentage of Participants With Oral Antifungal Started to Complete Therapy
Percentage of Participants With Documented Eradication of Infecting Species
Percentage of Participants With Resolution of Signs of Infection According to Ultrasound Scan Results
Percentage of Participants With Resolution of Signs of Infection According to Computerized Tomography (CT) Scan Results
Percentage of Participants With Abnormal Results for Liver Function at Initiation of Drug Therapy
Percentage of Participants With Abnormal Results for Liver Function at End of Drug Therapy
Percentage of Participants With Liver Function Test Results at Least Twice the Baseline Value During Period of Drug Therapy
Percentage of Participants With Creatinine Clearance at Least Twice the Baseline Value During Period of Drug Therapy
Percentage of Participants Admitted to Liver Intensive Therapy Unit (LITU)
Duration of Stay at Liver Intensive Therapy Unit (LITU)
Percentage of Participants With Absolute Neutrophil Count Less Than 500 Per Cubic Millimeter (/mm^3) and Greater Than or Equal to 500 /mm^3
Percentage of Participants With Concomitant Bacterial or Viral Infection
Percentage of Participants Prescribed With Systemic Antifungal Within 30 Days Before Study Start
Dose Changes for Immunosuppressant Drugs
Percentage of Participants With Probable or Proven Fungal Infection at the Initiation of Drug Therapy
Percentage of Participants With Documented Body Temperature Above 38.0 Degree Celsius or Below 36.0 Degree Celsius Within 24 Hour Period Prior to Initiation of Drug Therapy
Percentage of Participants With Systolic Blood Pressure More Than 2 Standard Deviations Below the Mean for Age Recorded Within 24 Hour Period Prior to Initiation of Drug Therapy
Number of Participants With Infection Sites as Per Microbiological Analysis
Number of Participants With Infection Sites as Per Ultrasound Scan and Computerized Tomography (CT) Scan
Infecting Organisms by Species
Percentage of Participants With Prior Colonization With Candida by Species
Percentage of Participants With Prior Colonization With Candida by Colonization Index
Percentage of Participants With Other Prior Fungal Infection by Species and Colonization Index
Number of Participants Who Received Water-based and Ethanol-based Formulation
Percentage of Participants Who Received Water-based and Ethanol-based Formulation
Percentage of Participants Who Received 200 mg Loading Dose
Percentage of Participants Who Received 100 mg Dose on Day 2
Percentage of Participants Who Received 200 mg Dose on Day 1 and 100 mg for All Subsequent Doses
Number of Participants With Other Dosing Patterns
Duration of Anidulafungin Therapy
Number of Serious Adverse Events (SAEs)
Percentage of Participants With One or More Drug-related Serious Adverse Events (SAEs)
Number of Participants With Different Types of Drug-related Serious Adverse Events
Minimum age: 18 Years.
Maximum age: 90 Years.
Gender(s): Both.